Mineralys Therapeutics to present new lorundrostat Launch-HTN data at ASN Kidney Week 2026

• Mineralys Therapeutics disclosed new Launch-HTN trial data on lorundrostat will be presented at ASN Kidney Week 2026 in Denver.
• The presentation is set for Oct. 21-25, covering patients with chronic kidney disease stages 1 to 3.
• Results show lorundrostat reduced blood pressure, with a separate improvement in albuminuria, supporting its potential in kidney-related hypertension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610021630PRIMZONEFULLFEED9838938) on October 02, 2026, and is solely responsible for the information contained therein.